Estimates Revisions Keymed Biosciences Inc.
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
|
Market Closed -
Hong Kong S.E.
04:08:08 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 80.30 HKD | +3.28% |
|
+1.45% | +50.23% |
| 08-19 | Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-09 | Keymed Biosciences' Nasal Polyp Drug Trial Meets All Phase 2 Endpoints | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- 2162 Stock
- Consensus Keymed Biosciences Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
